153 related articles for article (PubMed ID: 30703342)
21. FAM46C Serves as a Predictor of Hepatic Recurrence in Patients with Resectable Gastric Cancer.
Tanaka H; Kanda M; Shimizu D; Tanaka C; Kobayashi D; Hayashi M; Iwata N; Yamada S; Fujii T; Nakayama G; Sugimoto H; Fujiwara M; Niwa Y; Kodera Y
Ann Surg Oncol; 2017 Oct; 24(11):3438-3445. PubMed ID: 27770343
[TBL] [Abstract][Full Text] [Related]
22. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
23. Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients.
Sakamoto Y; Ohyama S; Yamamoto J; Yamada K; Seki M; Ohta K; Kokudo N; Yamaguchi T; Muto T; Makuuchi M
Surgery; 2003 May; 133(5):507-11. PubMed ID: 12773978
[TBL] [Abstract][Full Text] [Related]
24. Initial and crucial genetic events in intestinal-type gastric intramucosal neoplasia.
Rokutan H; Abe H; Nakamura H; Ushiku T; Arakawa E; Hosoda F; Yachida S; Tsuji Y; Fujishiro M; Koike K; Totoki Y; Fukayama M; Shibata T
J Pathol; 2019 Apr; 247(4):494-504. PubMed ID: 30474112
[TBL] [Abstract][Full Text] [Related]
25. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
[TBL] [Abstract][Full Text] [Related]
26. Mutational analysis by next generation sequencing of gastric type dysplasia occurring in hyperplastic polyps of the stomach: Mutations in gastric hyperplastic polyps.
Salomao M; Luna AM; Sepulveda JL; Sepulveda AR
Exp Mol Pathol; 2015 Dec; 99(3):468-73. PubMed ID: 26325218
[TBL] [Abstract][Full Text] [Related]
27. Circulating microRNA-203 predicts metastases, early recurrence, and poor prognosis in human gastric cancer.
Imaoka H; Toiyama Y; Okigami M; Yasuda H; Saigusa S; Ohi M; Tanaka K; Inoue Y; Mohri Y; Kusunoki M
Gastric Cancer; 2016 Jul; 19(3):744-53. PubMed ID: 26233325
[TBL] [Abstract][Full Text] [Related]
28. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
29. CCNE1 amplification is associated with liver metastasis in gastric carcinoma.
Kim B; Shin HC; Heo YJ; Ha SY; Jang KT; Kim ST; Kang WK; Lee J; Kim KM
Pathol Res Pract; 2019 Aug; 215(8):152434. PubMed ID: 31178228
[TBL] [Abstract][Full Text] [Related]
30. A system for detecting high impact-low frequency mutations in primary tumors and metastases.
Anjanappa M; Hao Y; Simpson ER; Bhat-Nakshatri P; Nelson JB; Tersey SA; Mirmira RG; Cohen-Gadol AA; Saadatzadeh MR; Li L; Fang F; Nephew KP; Miller KD; Liu Y; Nakshatri H
Oncogene; 2018 Jan; 37(2):185-196. PubMed ID: 28892047
[TBL] [Abstract][Full Text] [Related]
31. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
32. Identification of DNA mutations in gastric washes from gastric adenocarcinoma patients: Possible implications for liquid biopsies and patient follow-up.
Pizzi MP; Bartelli TF; Pelosof AG; Freitas HC; Begnami MD; de Abrantes LLS; Sztokfisz C; Valieris R; Knebel FH; Coelho LGV; da Costa WL; Coimbra FJF; da Silva IT; de Amorim MG; Nunes DN; Dias-Neto E
Int J Cancer; 2019 Aug; 145(4):1090-1098. PubMed ID: 30779121
[TBL] [Abstract][Full Text] [Related]
33. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
34. [Indication and meaning of hepatic resection for metastatic liver tumors from gastric cancer].
Noda K; Umekita N; Shiba Y; Ookubo T; Inoue S; Kitamura M
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1688-90. PubMed ID: 16315910
[TBL] [Abstract][Full Text] [Related]
35. Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.
Kogita A; Yoshioka Y; Sakai K; Togashi Y; Sogabe S; Nakai T; Okuno K; Nishio K
Biochem Biophys Res Commun; 2015 Feb; 458(1):52-6. PubMed ID: 25623536
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis.
Bria E; Pilotto S; Simbolo M; Fassan M; de Manzoni G; Carbognin L; Sperduti I; Brunelli M; Cataldo I; Tomezzoli A; Mafficini A; Turri G; Karachaliou N; Rosell R; Tortora G; Scarpa A
Sci Rep; 2016 Mar; 6():22982. PubMed ID: 26961069
[TBL] [Abstract][Full Text] [Related]
37. Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.
Valtcheva N; Lang FM; Noske A; Samartzis EP; Schmidt AM; Bellini E; Fink D; Moch H; Rechsteiner M; Dedes KJ; Wild PJ
BMC Cancer; 2017 Jan; 17(1):66. PubMed ID: 28103826
[TBL] [Abstract][Full Text] [Related]
38. Targeted next-generation sequencing of well-differentiated rectal, gastric, and appendiceal neuroendocrine tumors to identify potential targets.
Park HY; Kwon MJ; Kang HS; Kim YJ; Kim NY; Kim MJ; Min KW; Choi KC; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Lee HK
Hum Pathol; 2019 May; 87():83-94. PubMed ID: 30851333
[TBL] [Abstract][Full Text] [Related]
39. PIK3CA somatic mutations as potential biomarker for immunotherapy in elder or TP53 mutated gastric cancer patients.
Yao J; You Q; Zhang X; Zhang Y; Xu J; Zhao X; Li J; Wang X; Gong Z; Zhang D; Wang W
Clin Genet; 2023 Feb; 103(2):200-208. PubMed ID: 36346122
[TBL] [Abstract][Full Text] [Related]
40. Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix.
Xing D; Zheng G; Schoolmeester JK; Li Z; Pallavajjala A; Haley L; Conner MG; Vang R; Hung CF; Wu TC; Ronnett BM
Am J Surg Pathol; 2018 Jun; 42(6):750-760. PubMed ID: 29505425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
